Myasthenia Gravis Therapeutics Pipeline to have Maximum Drugs to be Developed as Biologics: P&S Market Research

NEW YORK, March 27, 2018 -- According to a new research report titled “Myasthenia Gravis Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Myasthenia Gravis currently exhibits a pipeline of 19 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/report-sample

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

Browse Full Report with detailed TOC on “Myasthenia Gravis Therapeutics Pipeline” at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

More Reports Published by P&S Market Research

Post-Operative Pain Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis

FRDA Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/frda-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook